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INTRODUCTION
Fulminant hepatic failure (FHF) is an infrequent but 
dreadful disease, defined by the appearance of  hepatic 
encephalopathy within 8 wk after the onset of  jaundice 
in patients with no known chronic liver disease[1]. Most 
FHF patients rapidly develop electrolyte, metabolic, 
and coagulation abnormalities[2]. They frequently suffer 
from acute renal insufficiency and/or adult respiratory 
distress syndrome (ARDS), leading to multiple organ 
failure (MOF)[3]. They are very sensitive to infection, and 
frequently develop a sepsis-like syndrome, with systemic 
hypotension, low peripheral resistance and increased 
cardiac output. Modern intensive care units (ICU) have 
learned to treat all these conditions, and have prolonged 
FHF patient survival. However, in absence of  liver 
transplantation (LT), the mortality rate of  FHF patients 
remains high (60%-80%). Causes of  death of  these 
patients are mainly MOF, sepsis, and/or brain edema 
leading to intracranial hypertension and secondary brain 
death. 
Brain edema in FHF patients is a relatively recent 
concept. In a 1944 report of  125 autopsies of  military 
patients dying from what was called fatal hepatitis 
(previously named idiopathic acute yellow atrophy of  the 
liver), Lucké noted little alteration in the brain, except 
edema, but he did not describe cerebral herniation[4]. He 
hypothesized that the cerebral changes of  fatal hepatitis 
might be attributed to loss of  detoxifying function of  
the liver. The first reports of  brain edema and cerebral 
herniation as complications of  FHF were published in 
the 1970’s[5,6] and were criticized at that time. Widespread 
recognition that brain edema and intracranial hypertension 
are complications of  FHF only occurred in the 1980’s[7,8]. 
It is also very interesting to note that brain edema and 
intracranial hypertension are not recognized common 
features of  terminal chronic liver failure, despite some 
case reports or small series[9,10]. The recent recognition of  
brain edema in FHF patients could be due to the advances 
in FHF patient care. Previously, FHF patients were dying 
from early hepatocellular insufficiency complications, 
mainly hemorrhage or sepsis[4]. Improvements in ICU 
techniques have lengthened the survival of  FHF patients. 
The longer course of  the disease may have allowed the 
development of  brain edema, possibly a later complication 
of  FHF (F igure 1 ) . S ign i f i cant advances in the 
understanding of  FHF brain edema have been made this 
last decade, but the exact pathophysiological mechanisms 
underlying development of  brain edema and intracranial 
hypertension in FHF are still not entirely clear and are 
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Abstract
Intracranial hypertension is a major cause of morbidity 
and mortality of patients suffering from fulminant 
hepatic fai lure. The et iology of this intracranial 
hypertension is not fully determined, and is probably 
multifactorial, combining a cytotoxic brain edema due 
to the astrocytic accumulation of glutamine, and an 
increase in cerebral blood volume and cerebral blood 
fl ow, in part due to infl ammation, to glutamine and to 
toxic products of the diseased liver. Validated methods 
to control intracranial hypertension in fulminant hepatic 
failure patients mainly include mannitol, hypertonic 
saline, indomethacin, thiopental, and hyperventilation. 
However all these measures are often not sufficient 
in absence of liver transplantation, the only curative 
treatment of intracranial hypertension in fulminant 
hepatic failure to date. Induced moderate hypothermia 
seems very promising in this setting, but has to be 
validated by a controlled, randomized study. Artificial 
liver support systems have been under investigation 
for many decades. The bioartifi cial liver, based on both 
detoxification and swine liver cells, has shown some 
effi cacy on reduction of intracranial pressure but did not 
show survival benefi t in a controlled, randomized study. 
The Molecular Adsorbents Recirculating System (MARS) 
has shown some efficacy in decreasing intracranial 
pressure in an animal model of liver failure, but has still 
to be evaluated in a phase Ⅲ trial. 
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likely to be multifactorial[11]. The aim of  this paper is to 
review the pathophysiology of  intracranial hypertension in 
FHF in order to improve understanding and management 
of  this complication.
PATHOPHYSIOLOGY OF INTRACRANIAL 
HYPERTENSION IN FHF
Normal intracranial pressure (ICP) is 5 to 10 mmHg 
and intracranial hypertension becomes clinically relevant 
when ICP exceeds 20 mmHg. The main complication 
of  severe intracranial hypertension in FHF patients 
is transtentorial herniation[12]. This herniation may 
induce (1) compression of  the posterior cerebral artery, 
leading to medial temporal, thalamic, and occipital lobe 
infarction; (2) cerebral aqueduct and subarachnoid space 
compression, causing obstructive hydrocephalus; and (3) 
brain stem compression, resulting in brain stem ischemia, 
haemorrhage, and death[12]. Additionally, severe intracranial 
hypertension compromises cerebral perfusion pressure 
(CPP). By defi nition, CPP is the difference between mean 
arterial pressure (MAP) and cerebral venous pressure. As 
cerebral venous pressure can be approximated by ICP, 
CPP equals MAP minus ICP[12,13]. An increase in ICP 
reduces CPP, and thus a decrease in cerebral blood fl ow 
(CBF). This reduction in CBF may cause cerebral ischemia 
or infarction, resulting in neurological deficits in FHF 
survivors. 
A rise in ICP is the mechanical consequence of  an 
increase in the intracranial volume. The central nervous 
system (CNS) is protected by the skull, which is rigid and 
incompressible. Inside the skull, 3 different compartments 
can be defined: the brain, the cerebrospinal fluid (CSF) 
and the blood. If  the volume of  one of  these elements 
increases, the volume of  another compartment might 
decrease, resulting in some intracranial compensation 
capacity or compliance. If  the increase in volume exceeds 
this compliance, any further addition of  volume leads to a 
rise in ICP. 
It is generally accepted that CSF volume is not 
expanded in FHF. During episodes of  intracranial 
hypertension in FHF, ventricular spaces measured by 
computed tomography (CT) were either unchanged or 
compressed, suggesting an increase in the brain tissue or 
blood volume[14,15]. In animal models and in FHF patients 
there is increased brain volume, secondary to edema[5,16,17]. 
In this environment even a small increase in cerebral 
blood volume could significantly increase ICP. In fact, 
these two phenomena have been proposed to account 
for intracranial hypertension in FHF: (1) brain edema 
due to osmotic astrocyte swelling secondary to ammonia-
induced accumulation of  glutamine (ammonia-glutamine 
hypothesis); (2) alteration of  CBF regulation with increase 
of  the intracranial blood volume.
Brain edema in FHF (Figure 2)
Both vasogenic and cytotoxic mechanisms are implicated 
in the development of  cerebral edema. Vasogenic brain 
edema occurs as a result of  the disruption of  the blood-
brain barrier (BBB), allowing uncontrolled access of  
plasma components and water to the extracellular cerebral 
compartment. Cytotoxic edema is the consequence of  
impaired cellular osmoregulation in the brain, resulting 
in an increase of  cellular water. In FHF, evidence from 
experimental animals and postmortem human brain 
supports aspects of  each of  these mechanisms, but it is 
now well established that brain edema in FHF is mainly 
cytotoxic[18]. In several models of  FHF, compounds to 
which the BBB is normally impermeable (Evans Blue 
or a-aminoisobutyric acid) were detected in the brain 
in increased concentrations[19-21]. These observations 
suggest that BBB permeability is altered in FHF, which 
is consistent with a vasogenic mechanism. However, 
the ability of  mannitol to reduce ICP in patients with 
FHF indicates that the BBB remains largely intact[8]. 
Furthermore, electron microscopic studies of  human 
brain tissue in FHF revealed no alteration in the integrity 
of  tight junctions[22]. Moreover, consistent with cytotoxic 
edema, marked intracellular swelling of  perivascular 
astrocytes was observed. Recent magnetic resonance 
imaging of  brain of  FHF patients confirmed the 
predominant cytotoxic character of  FHF brain edema[23]. 
This suggests that FHF brain edema primarily develops 
within the cellular component of  the brain as a cytotoxic 
edema, and changes in the permeability of  the BBB may 
represent secondary events that could exacerbate edema or 
intracranial hypertension.
The ammonia-glutamine hypothesis: Cor t ica l 
astrocyte swelling is the most common obser-vation 
A
B
Figure 1  Computed tomography (CT) (sagittal sections) of the brain of a 17-year 
old man who developed fulminant hepatic failure. A: first CT performed in 
encephalopathy stage IV; B: control CT performed when the patient developed 
unilateral fixed midriasis, showing diffuse edema, compression of the fourth 
ventricle and of the brain stem. The patient developed brain stem death while 
waiting liver transplantation, despite medical therapy and MARS treatment.
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in neuropathological studies of  brain edema in FHF. 
Astrocytes are the most numerous cell type in the brain 
and occupy about one-third of  the cortical volume[24]. 
Astrocytes have several critical metabolic functions 
involved in the maintenance and regulation of  the 
extracellular microenvironment. They participate in water 
regulation in the brain, detoxify ammonia and maintain 
normal levels of  extracellular glutamate. Hyperammonemia 
is prevalent in acute liver failure. In the brain, ammonia 
i s de tox i f i ed to g lu tamine v ia the amidat ion of  
glutamate by an astrocytic enzyme, glutamine synthetase. 
Glutamine leaves the astrocyte by passive diffusion into 
the extracellular space where it is taken up by neurons 
and converted to glutamate. There is clear evidence 
of  increased brain glutamine concentrations in animal 
FHF models[25] and in postmortem samples of  FHF[26]. 
Brusilow fi rst proposed that this glutamine accumulation 
is the link between hyperammonemia and edema via 
altered osmoregulation[27]. In astrocyte cultures, ammonia 
induces cell swelling[17,28]. Brain swelling and intracranial 
hypertension have been documented in humans with 
hyperammonemic conditions[29]. In rats, a continuous 
infusion of  ammonia is associated with brain edema or 
intracranial hypertension[30] which is reduced by inhibition 
of  glutamine synthesis with methionine-sulfoximine[31-33]. 
The relationship between hyperammonemia, glutamine and 
ICP was recently demonstrated in humans[34]. Although 
there is much clinical and experimental evidence in support 
of  the glutamine hypothesis, prevention of  brain edema 
in FHF by inhibition of  glutamine synthesis has not been 
successful in humans.
Increase in cerebral blood flow and intracranial blood 
volume
Another phenomenon that has also been involved in 
intracranial hypertension in FHF is the increase of  
intracranial blood volume and CBF. Some reports describe 
decreased CBF in patients suffering from acute liver 
failure[35,36], but most have found high CBF associated 
with intracranial hypertension in FHF[37,38]. Paulson 
suggests that an impairment of  vascular autoregulation 
in the brain could be responsible for this increase in CBF 
and blood volume[39]. Impaired autoregulation of  CBF 
has been reported in animal models of  FHF[40] and in 
patients with FHF[41]. The exact cause of  this increase 
of  CBF in FHF is not known. Nitric oxide (NO) has 
been implicated but it is possible that the increased NO 
in the brain of  FHF patients is secondary to an increase 
in CBF, rather than a primary event[18,42]. Inflammation 
markers (IL-1 β, TNF α, IL-6) and systemic infl ammatory 
response have been associated with increased CBF and 
ICP in FHF[37,43], and poor outcome[44]. The association 
of  systemic inflammation and impaired regulation of  
CBF might be related to the role of  the necrotic liver 
in intracranial hypertension in FHF. The observation 
that brain edema and intracranial hypertension are 
complications of  FHF and not of  chronic liver disease 
lead to the hypothesis that these phenomena may in part 
result from products of  the acutely necrotic liver. There is 
experimental and clinical evidence to support this theory, 
the “toxic liver hypothesis”. In a rat model, cerebral 
edema was significantly lower in anhepatic than FHF 
animals[45]. In pigs, no elevation of  ICP was observed after 
total hepatectomy, whereas a rise in ICP was observed in 
pigs with FHF secondary to ischemia[46]. Several human 
observations reinforced this hypothesis. During LT for 
FHF, it was established that ICP normalizes during the 
anhepatic phase and may increase during the dissection 
of  the diseased liver and during graft reperfusion[47,48]. 
The removal of  the diseased liver has been linked to ICP 
normalization and to marked and sustained reduction of  
several pro-inflammatory cytokines in a case report[49]. 
Moreover some patients underwent prolonged period 
(up to 72 h) of  anhepatic state without neurological 
sequelae[50,51]. Although these fi ndings are suggestive, the 
role of  products from the necrotic liver in cerebral edema 
and intracranial hypertension is still unknown. 
The respective role of  all of  these phenomena in the 
development of  intracranial hypertension in FHF remains 
to be determined. It can be hypothesized that brain edema 
(increase in brain volume) secondary to osmotic effect of  
glutamine in astrocytes, and cerebral hyperemia (increase 
in blood volume) secondary to vasodilation (cytokines, 
products of  the necrotic liver, glutamine, others…) may 
contribute to intracranial hypertension leading to brain 
stem herniation and brain stem death in FHF. During all 
these FHF phenomena, the brain may respond by altering 
the expression of  genes coding for various proteins whose 
role may be critical to some CNS functions, including 
the maintenance of  cell volume and neurotransmission. 
Cerebral gene expression during FHF is modified as 
demonstrated by differential display in rat models[52,53]. 
Some genes have been more specifically studied, as 
GLUT-1[54], aquaporin IV[55], GLT-1[52,56] and others[57]. The 
exact role of  this gene expression observed during FHF is 
still to be determined.
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Figure 2  Schematic representation of the hypotheses explaining intracranial 
hypertension and brain stem death in fulminant hepatic failure.
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D I A G N O S I S O F I N T R A C R A N I A L 
HYPERTENSION IN FHF PATIENTS
Intracranial hypertension should clinically be suspected 
in FHF patients with systemic hypertension (sustained ≥
160 mmHg or paroxysms ≥ 200 mmHg), aggravation of  
hepatic encephalopathy, abnormal pupillary signs, or signs 
of  decerebration. However, most of  these clinical signs are 
not specifi c, and may be developed by patients in hepatic 
grade IV encephalopathy without intracranial hypertension. 
It was reported that brain CT is unreliable in the diagnosis 
of  intracranial hypertension in FHF patients[14], and there 
have been no reports of  the value of  brain magnetic 
resonance imaging in FHF patients for confirming the 
diagnosis of  intracranial hypertension. The most accurate 
method of  diagnosing intracranial hypertension is ICP 
monitoring. Although the advantages of  this monitoring 
in FHF patients have not yet been demonstrated by a 
randomized study, ICP monitoring may be very helpful 
in establishing the presence of  intracranial hypertension 
and in guiding specifi c therapy. Intracranial hypertension 
in FHF patients may suddenly rise from normal to 
life threatening levels within minutes. In this situation, 
continuous ICP monitoring may allow rapid and specifi c 
management. Several groups have included ICP monitoring 
in the protocol of  FHF patient management[14,47,58]. The 
main argument against ICP monitoring is the enhanced 
risk of  complications in FHF patients, mainly infection 
and hemorrhage. In a national survey of  262 FHF patients, 
the complication rate of  ICP monitoring was 10%. In this 
series, intracranial hemorrhages were the cause of  death 
in 7 patients and the epidural transducers had the lowest 
complication rate (3.7%)[59]. The complication rate of  ICP 
monitoring in FHF patients was reported to be lower in a 
recent multicenter report, but is still signifi cant[60].
MANAGEMENT OF INTRACRANIAL 
HYPERTENSION IN FHF PATIENTS
General management of  FHF patients is beyond the scope 
of  this review and was presented elsewhere[2]. The goal in 
the medical management of  FHF patients with intracranial 
hypertension is to maintain ICP below 20 mmHg and CPP 
above 70 mmHg. Cerebral ischemia occurs if  CPP is less 
than 40 to 50 mmHg, and LT should be contraindicated 
if  CPP remains below 40 mmHg for two hours[61]. This 
goal requires intense medical management and nursing. 
FHF patients should be admitted to ICU in an institution 
with an active liver transplant program. FHF patients 
should be monitored with peripheral arterial catheters. 
Vital signs, urinary output, arterial blood gases and 
central hemodynamic parameters should be continuously 
monitored. FHF patients are treated with standard 
supportive measures to correct electrolyte, metabolic, 
respiratory and hemodynamic abnormalities. Hypovolemia 
may exacerbate hypotension, and may reduce CPP, 
inducing brain ischemia. Systemic hypertension may also 
be deleterious by increasing ICP[62]. In this case, ß-blockers 
may be more useful than nitroprusside or calcium-channel 
inhibitors, because of  their potential risk of  brain blood 
vessel dilatation. Patient positioning and nursing is also 
important in the care of  FHF patients with intracranial 
hypertension. The head should be in the midline because 
neck rotation or fl exion may compromise jugular venous 
drainage and increase ICP. Head and chest elevation may 
lower ICP by enhancing CSF drainage and maximizing 
cerebral venous output[12]. However, the efficacy of  this 
positioning in FHF patients is yet to be proven and further 
elevations to 40° and 60° may paradoxically increase 
ICP[63]. Environmental stimulation should be maintained 
at a minimal level. Most of  the FHF patients with 
encephalopathy grade III/IV are endotracheally intubated 
to provide airway protection and/or ventilation support. 
This ventilation may promote some ICP fluctuation. 
Moreover, positive end-expiratory pressure (PEEP) may 
increase ICP when mean airway pressures are increased 
and should be used carefully[12]. Straining against the 
mechanical ventilator may increase intrathoracic pressure 
and reduce venous outflow from the head. Coughing, 
which is a frequent reflex to tracheal tube aspiration, 
should be avoided for the same reason. Therefore, if  
necessary, the patient is sedated and/or paralyzed with 
nondepolarizing neuromuscular blockers.
Specifi c treatment of  intracranial hypertension in FHF 
patients is aimed at the culprit underlying pathophysiology, 
for example therapy to reduce brain volume or lower ICP 
by reducing intracranial blood volume and CBF.
Treatments To decrease brain volume
As hyperammonemia is considered responsible for the 
cytotoxic brain edema, it seems logical to try to reduce 
ammonia in FHF patients. There is no randomized study 
on the effects of  lactulose in FHF. In a retrospective 
study, lactulose administration did not change the outcome 
of  treated patients, and the routine use of  lactulose is 
not recommended[64]. The use of  intravenous mannitol 
improved the survival and decreased the ICP level in a 
controlled trial[8]. Mannitol (0.5 to 1 g/kg iv every 6  h, 
blood osmolarity < 310 mosmol/L) increases blood 
osmolarity, thereby inducing fluid movement from brain 
to blood. Therefore, the effi cacy of  mannitol depends on 
an intact BBB. The efficacy of  mannitol to reduce ICP 
may be affected by acute renal failure and oliguria. In 
order to be able to use mannitol repeatedly, fl uid can be 
taken off  with hemofi ltration (up to 500 mL), which by itself  
reduces ICP[64]. Hypertonic saline has also been evaluated 
in a small controlled trial to prevent the occurrence of  
intracranial hypertension. Intravenous hypertonic saline 
(30%) to maintain serum sodium between 145-155 mmol/
L was compared with an untreated group. The treated 
group suffered smaller increases of  ICP[65]. By extension, 
hyponatremia should be avoided in FHF patients.
Treatments To decrease cerebral blood f low and 
intracranial blood volume
Hyperventilation: In non-FHF patients, hyperventilation 
induces ICP reduction through vasoconstriction of  
the brain blood vessels[12]. The duration of  this ICP 
reduction varies, and ICP usually returns to baseline 
within hours of  hyperventilation. In FHF patients, this 
effect of  hyperventilation on intracranial hypertension 
is not clear[7] but may help to restore cerebral blood fl ow 
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autoregulation[66]. From these observations, it can be stated 
that hyperventilation may reduce ICP acutely but should 
not be used over a prolonged period[64]. Indomethacin induces 
cerebral vasoconstriction through inhibition of  endothelial 
cyclooxygenase pathway, alterations in extracellular pH 
and reduction in cerebral temperature[64]. Indomethacin 
has been shown to reduce ICP in an animal model[67] and 
a small cohort of  12 patients[68], and should be evaluated 
in a randomized controlled study before wider use. 
Thiopental sodium has also been studied in FHF patients. Its 
administration results in cerebral vasoconstriction possibly 
by inhibition of  nitric synthase. There is only one small 
study in the literature involving 13 patients, that showed 
benefi cial effects of  thiopental on ICP but its effi cacy and 
side effects have to be evaluated in further randomized 
studies[69]. Propofol in a dose of  6 mg/kg per hour reduces 
CBF through metabolic suppression[64] and was used in a 
small report[70]. It could be the sedative of  choice in FHF 
patients. 
Liver transplantation
LT has emerged as the most important advance in the 
treatment of  FHF[58,71-74]. To date, transplantation of  a 
functioning graft is the best treatment to achieve control 
of  brain edema and intracranial hypertension. For 
this reason, every FHF patient should be referred to a 
transplant center and listed for LT if  transplant criteria are 
met (Table 1)[75,76]. However, some FHF patients in Grade 
Ⅳ encephalopathy may develop severe cerebral injury 
or brain death during the perioperative period, and these 
complications are believed to be secondary to perioperative 
ICP elevation or CPP reduction. For example, in a 
study from Paul Brousse’s group, 13 patients among 116 
(11.2%) who underwent LT for FHF developed brain 
death during or after the procedure, and 2 others suffered 
from neurological sequelae[74]. It was demonstrated that 
during LT, the dissection phase and the graft reperfusion 
are particularly at risk of  ICP elevation, and that the 
anhepatic phase seems to be more favorable with ICP 
normalization[47,48]. 
FUTURE PROSPECTS IN THE TREATMENT 
OF INTRACRANIAL HYPERTENSION OF 
FHF
Hypothermia
The effects of  moderate hypothermia (32℃-34℃) on 
ICP in FHF patients are currently being investigated. In 
rat models of  FHF, hypothermia lowered brain edema 
measured by a gravimetric technique, and prolonged 
survival[77,78]. Several reports have demonstrated that 
hypothermia causes a signifi cant decrease of  ICP in FHF 
patients[79,80]. Hypothermia could be a very effi cient therapy 
for patients with uncontrolled intracranial hypertension[81] 
and a multicenter, randomized, controlled trial should be 
conducted to defi nitively assess the role of  hypothermia in 
FHF patient management.
Liver assist systems
For more than 50 years, many research groups have 
attempted to support patients in acute liver failure as 
a bridge to LT or to recovery of  adequate native liver 
function. Development of  such a system presents a unique 
challenge as it has to reproduce an array of  complex liver 
functions. Moreover, the results of  this system has to 
be evaluated in very sick and unstable patients, in whom 
large, randomized, controlled trials are very difficult. 
Plasma exchange, plasmapheresis, blood exchange, 
hemodialysis, hemofi ltration, cross-circulation, and cross-
hemodialysis have all been tried without any benefit to 
patient survival[82]. Ex vivo whole (animal and/or human) 
liver perfusion might be promising in small series, but is 
limited by several drawbacks that are beyond the scope 
of  this review[82]. Recent advances in semipermeable 
membranes and hollow-fiber technologies, as well as 
improved techniques of  hepatocyte isolation, have allowed 
the development of  new liver support systems, that may 
be classifi ed as non-biological blood detoxifi cation systems 
and liver assist systems with biological components[82]. 
Two systems have achieved relatively large use in humans. 
The Molecular Adsorbents Recirculating System (MARS), 
which is based on the selective removal of  albumin-
bound toxins from the blood, is commercially available. 
In a small, randomized trial MARS was shown to improve 
survival of  patients suffering from acute-on-chronic liver 
failure[83], but controlled clinical data for the use of  MARS 
in FHF patients is lacking, especially its effect on ICP. 
Recently, it was demonstrated that MARS may attenuate 
(but not normalize) ICP in a pig model with ischemic liver 
failure[84]. MARS has still to prove its value in FHF patients 
in controlled trials. 
Mul t ip l e l ive r a s s i s t s y s tems w i th b io log ica l 
components have been tried, in order to construct a 
liver support that may provide not only detoxification, 
but also biotransformation and missing liver synthetic 
function[82]. A lot of  systems were based on isolated or 
cultured hepatocytes and liver tissue slices placed in a 
variety of  perfusion bioreactors[82]. Only one system has 
completed a controlled trial, the bioartifi cial liver (BAL). 
The BAL design is based both on a detoxification part 
and on a cartridge containing porcine hepatocyte and 
is explained elsewhere[82]. The BAL has shown some 
Table 1  Liver transplantation criteria in patients with fulminant 
hepatic failure
Clichy criteria (Hepatology 1991; 14: 49A)
Grade Ⅲ or Ⅳ encephalopathy and
         - factor Ⅴ level < 20% (patients younger than 30)
         - factor Ⅴ level < 30% (patients older than 30)
King’s College criteria (Modifi ed from Gastroenterology 1989; 97: 439-445)
Paracetamol intoxication:
         - pH < 7.3 or 
         - INR > 4 and serum creatinin > 300 μmol/L (> 34 mg/L) and grade 
           Ⅲ or Ⅳ encephalopathy
Other causes:
         - INR > 4 or
         - 3 of the following criteria:
 - age < 10 or > 40 years
 - etiology: NonA nonB hepatitis, halothane hepatitis, 
  idiosyncratic drug reactions
 - delay between jaundice and encephalopathy > 7 d
 - INR > 3.5
 - bilirubin > 300 μmol/L (> 175 mg/L)
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effi cacy to decrease ICP in FHF patients[85] and in patients 
suffering from acetaminophen-induced liver failure[86]. 
However a controlled, randomized trial did not show any 
improvement in survival in the BAL treated group[87] and 
the Circe company that produced the BAL, has stopped its 
activity. In conclusion, despite years of  scientifi c efforts, 
there is no (bio)artifi cial system that has proved its effi cacy 
on ICP control. The MARS seems promising but has still 
to prove its role on ICP in FHF patients. 
Hepatocyte Transplantation
Transplantation of  isolated hepatocytes has been shown to 
provide metabolic support and improve survival in various 
experimental models of  acute liver failure including 90% 
hepatectomy[88,89], D-galactosamine[90], acetaminophen[91] 
and ischemic models[92]. Hepatocyte transplantation also 
has been shown to improve chronic encephalopathy, 
induced by an end-to-side portocaval shunt in rats[93]. 
In a pig model of  ischemic liver failure, the intrasplenic 
transplantation of  hepatocytes allowed the transplanted 
animal to maintain normal ICP, compared to the treated 
group[46].
In two clinical reports, 12 patients were transplanted 
with a very small number of  hepatocytes (0.01%-0.4% of  
the liver mass) which were infused either intraperitoneally 
or intrasplenically[94,95]. Although both studies reported 
improvement in neurologic status and survival of  the 
transplanted patients, the limited number of  patients and 
the lack of  appropriate controls do not allow reliable 
conclusions to be reached. More experiments in large 
animal models are needed in order to investigate the 
“neuro-protective” potential of  transplanted hepatocytes. 
In addition, three major problems need to be solved 
before clinical application of  hepatocyte transplantation 
can be established: (1) how to harvest and store the 
maximum number of  functional hepatocytes from 
human liver (e.g. hepatic resection specimens, organs 
rejected for transplantation, etc); (2) how to safely perform 
transplantation of  a significant amount of  hepatocytes 
(at least 5% of  the liver mass) considering the anatomic 
limitations and the severe metabolic disturbances of  FHF 
patients (e.g. coagulopathy); (3) how to determine the 
optimal timing of  hepatocellular transplantation in the 
course of  FHF.
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